Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582790 · ClinicalTrials.gov registry record · Phase 2
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00582790 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 12 participants.
The verdict
NCT00582790, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is being done to see if we can improve the response of Interleukin-2 by adding Zoledronic acid. The effectiveness of the combination of drugs in kidney cancer is unknown and will be investigated in this study. In particular, this study will evaluate the effect of this combination on kidney cancer and will also examine the safety and side effects of IL-2 with Zoledronic acid.
Interventions
- DRUG Zoledronic acid
- DRUG IL2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2003-08 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582790
The ClinicalTrials.gov registry entry for NCT00582790 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zoledronic acid is the first listed.
NCT00582790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582790 about?
NCT00582790 is a clinical study titled "Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer". This study is being done to see if we can improve the response of Interleukin-2 by adding Zoledronic acid. The effectiveness of the combination of drugs in kidney cancer is unknown and will be investigated in this study. In particular, this study will evaluate the effect of this combination on kidne...
What is the current status of trial NCT00582790?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2003-08. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00582790?
The interventions under investigation include: Zoledronic acid (DRUG), IL2 (DRUG).
Who is sponsoring clinical trial NCT00582790?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.